Market News / Story
60 Degrees Pharmaceuticals to unblind hospitalized babesiosis study after enrolling 30; Jan 2027 readout planned
·
60 Degrees Pharmaceuticals will unblind its hospitalized babesiosis study after concluding enrollment at 30 patients and expects primary and secondary endpoint results in January 2027. Key Highlights: DSMB recommended completing the originally planned enrollment (33); company enrolled 30 and will proceed to unblinding. Company concluded additional enrollment adds minimal statistical benefit and seasonal recruitment would delay unblinding until Fall 2027. No safety…